公开(公告)号：US10577419B2

公开(公告)日：2020-03-03

申请号：US14662349

申请日：2015-03-19

Applicant: INNATE PHARMA

Inventor： Laurent Gauthier ,  Simon Kollnberger ,  Benjamin Rossi ,  Hélène Sicard ,  Carine Paturel ,  Stéphanie Cornen ,  Stéphanie Zerbib

IPC: C07K16/28 ,  G01N33/569 ,  A61K39/00

Abstract: The present invention relates to methods for the treatment of cancer and inflammatory disease using antibodies (e.g. monoclonal antibodies), antibody fragments, and derivatives thereof that specifically bind KIR3DL2. The invention also relates to antibodies, cells producing such antibodies; methods of making such antibodies; fragments, variants, and derivatives of the antibodies; pharmaceutical compositions comprising the same.

公开(公告)号：US20190389961A1

公开(公告)日：2019-12-26

申请号：US16477506

申请日：2018-03-16

Applicant: Innate Pharma

Inventor： Stéphanie Chanteux ,  Nicolas Gourdin ,  Carine Paturel ,  Ivan Perrot ,  Benjamin Rossi

IPC: C07K16/28 ,  A61P35/00 ,  A61K39/395 ,  A61K45/06 ,  G01N33/574

Abstract: The present invention relates to antigen-binding compounds that inhibit the enzymatic activity of soluble human CD39. The invention also relates to cells producing such compounds; methods of making such compounds, and antibodies, fragments, variants, and derivatives thereof; pharmaceutical compositions comprising the same; methods of using the compounds to diagnose, treat or prevent diseases, e.g., cancer.

公开(公告)号：US10246510B2

公开(公告)日：2019-04-02

申请号：US14429416

申请日：2013-09-17

Applicant: INNATE PHARMA

Inventor： Laurent Gauthier ,  Benjamin Rossi ,  Hélène Sicard ,  Carine Paturel

IPC: C07K16/28 ,  G01N33/569 ,  A61K47/68 ,  A61K39/00

Abstract: The present invention relates to methods for the treatment of cancer and inflammatory disease using antibodies (e.g. monoclonal antibodies), antibody fragments, and derivatives thereof that specifically bind KIR3DL2. The invention also relates to antibodies, cells producing such antibodies; methods of making such antibodies; fragments, variants, and derivatives of the antibodies; pharmaceutical compositions comprising the same.

公开(公告)号：US20190055315A1

公开(公告)日：2019-02-21

申请号：US16173150

申请日：2018-10-29

Applicant: INNATE PHARMA

Inventor： Laurent Gauthier ,  Nadia Anceriz ,  Ariane Morel ,  Benjamin Rossi

IPC: C07K16/28

Abstract: Multispecific proteins that bind and specifically redirect NK cells to lyse a target cell of interest are provided without non-specific activation of NK cells in absence of target cells. The proteins have utility in the treatment of disease, notably cancer or infectious disease.

公开(公告)号：US10113003B2

公开(公告)日：2018-10-30

申请号：US15190337

申请日：2016-06-23

Applicant: INNATE PHARMA

Inventor： Laurent Gauthier ,  Nadia Anceriz ,  Ariane Morel ,  Benjamin Rossi

IPC: A61K39/00 ,  C07K16/28

Abstract: Multispecific proteins that bind and specifically redirect NK cells to lyse a target cell of interest are provided without non-specific activation of NK cells in absence of target cells. The proteins have utility in the treatment of disease, notably cancer or infectious disease.

公开(公告)号：US09828427B2

公开(公告)日：2017-11-28

申请号：US14924786

申请日：2015-10-28

Applicant: INNATE PHARMA

Inventor： Nicolas Anfossi ,  Laurent Gauthier ,  Yannis Morel ,  Alessandro Moretta ,  Silvia Parolini ,  Benjamin Rossi

IPC: A61K39/00 ,  A61K39/395 ,  C07K16/28 ,  C07K16/30 ,  A61K45/06

CPC classification number: C07K16/2803 ,  A61K39/3955 ,  A61K45/06 ,  A61K2039/505 ,  C07K16/3061 ,  C07K2317/24 ,  C07K2317/31 ,  C07K2317/34 ,  C07K2317/41 ,  C07K2317/52 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/73 ,  C07K2317/732

Abstract: The present invention provides antigen-binding proteins capable of binding to KIR3D polypeptides. The antibodies have increased activity in the treatment of disorders characterized by KIR3DL2-expressing cells, particularly CD4+ T cells, including malignancies such as Mycosis Fungoides and Sézary Syndrome.